American Century Companies Inc. Acquires 2,891 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

American Century Companies Inc. lifted its holdings in Sera Prognostics, Inc. (NASDAQ:SERA) by 12.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,682 shares of the company’s stock after acquiring an additional 2,891 shares during the period. American Century Companies Inc. owned 0.08% of Sera Prognostics worth $152,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SERA. Ballentine Partners LLC bought a new stake in shares of Sera Prognostics in the 2nd quarter valued at approximately $294,000. Lake Street Advisors Group LLC bought a new stake in Sera Prognostics in the second quarter worth $144,000. Rhumbline Advisers bought a new stake in Sera Prognostics in the second quarter worth $190,000. Bank of New York Mellon Corp boosted its stake in Sera Prognostics by 100.2% during the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after buying an additional 75,441 shares during the period. Finally, Twelve Points Wealth Management LLC bought a new position in Sera Prognostics during the second quarter valued at $257,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Insider Buying and Selling

In other Sera Prognostics news, CFO Austin Aerts sold 6,760 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total value of $50,159.20. Following the transaction, the chief financial officer now owns 303,721 shares of the company’s stock, valued at $2,253,609.82. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Zhenya Lindgardt sold 12,327 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total transaction of $91,466.34. Following the transaction, the chief executive officer now directly owns 856,918 shares of the company’s stock, valued at approximately $6,358,331.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Austin Aerts sold 6,760 shares of Sera Prognostics stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total transaction of $50,159.20. Following the sale, the chief financial officer now directly owns 303,721 shares of the company’s stock, valued at $2,253,609.82. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 54,447 shares of company stock valued at $408,493. Insiders own 15.80% of the company’s stock.

Sera Prognostics Trading Up 4.2 %

Sera Prognostics stock opened at $7.21 on Friday. Sera Prognostics, Inc. has a 12-month low of $1.56 and a 12-month high of $12.35. The firm has a 50-day moving average price of $7.46 and a 200-day moving average price of $8.13. The firm has a market capitalization of $235.44 million, a PE ratio of -6.74 and a beta of 1.03.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.08 million. Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 11,843.79%. During the same period in the previous year, the business earned ($0.34) EPS. As a group, sell-side analysts predict that Sera Prognostics, Inc. will post -0.95 earnings per share for the current fiscal year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.